Editor Keri Losavio has been a professional editor and writer in the medical and financial fields for 20 years and joined the Wiley team in February 2014. She has written for and edited newsletters, magazines, personal memoirs, book proposals, dissertations, textbooks and more.
On Sept. 1, the U.S. Food & Drug Administration (FDA) announced that it is requiring revisions to the Boxed Warning for the Janus kinase (JAK) inhibitors Xeljanz/Xeljanz XR (tofacitinib), Olumiant (baricitinib) and Rinvoq (upadacitinib) to include information about the risks of serious heart-related events, cancer, blood clots and death.1 Recommendations for healthcare professionals will include…
As part of the ACR’s pledge to be a leader for inclusion and change for members, trainees, staff and rheumatology patients, the ACR is holding a special image competition in conjunction with ACR Convergence 2021 dedicated exclusively to images of rheumatic disease in skin of color. “We started discussing the lack of diversity in our…
We know a large percentage of the U.S. population falls into a vaccine-hesitant group. In fact, only 60% of Americans plan to be vaccinated against COVID-19, according to an article in The Atlantic.1 Given that rheumatology patients are among the vulnerable, we asked a handful of ACR/ARP members whether they have been vaccinated themselves and…
FDA News Release—On April 16, saying that alternative monoclonal antibody therapies authorized to treat patients with COVID-19 remain available, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and…
I read with interest the case report of a patient with lupus enteritis in the February 2021 issue of The Rheumatologist, and I thought the diagnostic approach and final diagnosis were very well presented; however, I noticed an omission which in my view is quite relevant to this patient’s overall management and to so many…
As founder and president of a large rheumatology group, Howard M. Busch, DO, says the pandemic has had a limited financial effect on many of the network’s clinics. Communication and technology have been key to adapting to the needs of patients and connecting with other providers during this critical time.
On Dec. 10, the Supreme Court of the United States of America (SCOTUS) issued a landmark decision in Rutledge, Attorney General of Arkansas, v. Pharmaceutical Care Management Association. In an 8–0 decision, the justices agreed that states have the right to impose regulations on pharmacy benefit managers (PBMs), companies that manage prescription drug benefits on…
Short-term concomitant use of MMF with pegloticase was generally well tolerated in this proof-of-concept study. It was associated with a statistically significant and clinically meaningful impact on the proportion of subjects achieving and maintaining a sUA ≤6 mg/dL at 24 weeks. See the abstract with bonus video discussing the validation of proposed remission and completion criteria for the treatment of gout.
“It’s like winning Powerball.” For months, there has been a steady trickle of questions from my patients, asking for my opinion about the new vaccines being developed to prevent COVID-19. More to the point, they want to know if they should be vaccinated. After some fits and starts, I finally struck upon a pat answer…
In case you missed it, on Nov. 20, the Centers for Medicare & Medicaid Services (CMS), a department within the U.S. Department of Health and Human Services, announced that it will overhaul the payment system for Medicare Part B (i.e., infusion) drugs on Jan. 1, 2021. The plan is called the Most Favored Nation (MFN)…